Literature DB >> 22239224

Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer.

Stephen Langley1, Hashim U Ahmed, Bashar Al-Qaisieh, David Bostwick, Louise Dickinson, Francisco Gomez Veiga, Peter Grimm, Stefan Machtens, Ferran Guedea, Mark Emberton.   

Abstract

What's known on the subject? and What does the study add? Whole gland brachytherapy has been used to successfully treat prostate cancer but the protocol for focal therapy has not previously been established. The consensus findings provide guidance on patient selection for focal brachytherapy as well as recommendations for conducting therapy and patient follow-up. Low dose rate prostate brachytherapy is an effective treatment for localized prostate cancer. Recently, it has been considered for use in a focused manner whereby treatment is targeted only to areas of prostate cancer. The objective of focal brachytherapy is to provide effective cancer control for low-risk disease but with reduced genitourinary and rectal side-effects in a cost-effective way. We report on the outputs of a consensus meeting of international experts in brachytherapy and focal therapy convened to consider the feasibility and potential development of focal brachytherapy. A number of factors were considered for focal brachytherapy including optimal patient selection, disease characterization and localization, treatment protocols and outcome measures. The consensus meeting also addressed the design of a clinical trial that would assess the oncological outcomes and side-effect profiles resulting from focal brachytherapy.
© 2012 The Authors. BJU International © 2012 BJU International.

Entities:  

Mesh:

Year:  2012        PMID: 22239224     DOI: 10.1111/j.1464-410X.2011.10825.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  22 in total

1.  Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.

Authors:  Amar U Kishan; Sang J Park; Christopher R King; Kristofer Roberts; Patrick A Kupelian; Michael L Steinberg; Mitchell Kamrava
Journal:  Br J Radiol       Date:  2015-10-14       Impact factor: 3.039

Review 2.  Current trends and new frontiers in focal therapy for localized prostate cancer.

Authors:  Melissa H Mendez; Daniel Y Joh; Rajan Gupta; Thomas J Polascik
Journal:  Curr Urol Rep       Date:  2015-06       Impact factor: 3.092

3.  Role of MRI for the detection of prostate cancer.

Authors:  Richard C Wu; Amir H Lebastchi; Boris A Hadaschik; Mark Emberton; Caroline Moore; Pilar Laguna; Jurgen J Fütterer; Arvin K George
Journal:  World J Urol       Date:  2021-01-04       Impact factor: 4.226

4.  Combination of multiparametric magnetic resonance imaging and transrectal ultrasound-guided prostate biopsies is not enough for identifying patients eligible for hemiablative focal therapy for prostate cancer.

Authors:  Young Hyo Choi; Ji Woong Yu; Min Yong Kang; Hyun Hwan Sung; Byong Chang Jeong; Seong Il Seo; Seong Soo Jeon; Hyun Moo Lee; Hwang Gyun Jeon
Journal:  World J Urol       Date:  2019-01-02       Impact factor: 4.226

Review 5.  [Focal prostate cancer therapy: capabilities, limitations and prospects].

Authors:  D Baumunk; A Blana; R Ganzer; T Henkel; J Köllermann; A Roosen; S Machtens; G Salomon; L Sentker; U Witzsch; K U Köhrmann; M Schostak
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

Review 6.  The prostate cancer focal therapy.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Edoardo Zanchetta; Chiara Floridi; Gianpaolo Carrafiello; Chloë Standaert
Journal:  Gland Surg       Date:  2018-04

7.  Deformable registration of PET/CT and ultrasound for disease-targeted focal prostate brachytherapy.

Authors:  Sharmin Sultana; Daniel Y Song; Junghoon Lee
Journal:  J Med Imaging (Bellingham)       Date:  2019-09-12

8.  Focal therapy for localised unifocal and multifocal prostate cancer: a prospective development study.

Authors:  Hashim U Ahmed; Richard G Hindley; Louise Dickinson; Alex Freeman; Alex P Kirkham; Mahua Sahu; Rebecca Scott; Clare Allen; Jan Van der Meulen; Mark Emberton
Journal:  Lancet Oncol       Date:  2012-04-17       Impact factor: 41.316

9.  Current status of brachytherapy for prostate cancer.

Authors:  Dong Soo Park
Journal:  Korean J Urol       Date:  2012-11-14

Review 10.  Focal low-dose rate brachytherapy for the treatment of prostate cancer.

Authors:  William Y Tong; Gilad Cohen; Yoshiya Yamada
Journal:  Cancer Manag Res       Date:  2013-09-13       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.